Literature DB >> 17251918

Myelodysplastic syndromes: the complexity of stem-cell diseases.

Seth J Corey1, Mark D Minden, Dwayne L Barber, Hagop Kantarjian, Jean C Y Wang, Aaron D Schimmer.   

Abstract

The prevalence of patients with myelodysplastic syndromes (MDS) is increasing owing to an ageing population and increased awareness of these diseases. MDS represent many different conditions, not just a single disease, that are grouped together by several clinical characteristics. A striking feature of MDS is genetic instability, and a large proportion of cases result in acute myeloid leukaemia (AML). We Review three emerging principles of MDS biology: stem-cell dysfunction and the overlap with AML, genetic instability and the deregulation of apoptosis, in the context of inherited bone marrow-failure syndromes, and treatment-related MDS and AML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251918     DOI: 10.1038/nrc2047

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  126 in total

1.  From famine to feast: sending out the clones.

Authors:  Taly Glaubach; Seth J Corey
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

Review 2.  Energy metabolism and drug response in myeloid leukaemic stem cells.

Authors:  Alfonso E Bencomo-Alvarez; Andres J Rubio; Mayra A Gonzalez; Anna M Eiring
Journal:  Br J Haematol       Date:  2019-06-24       Impact factor: 6.998

3.  Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes.

Authors:  Xiaomei Ma; Rong Wang; Naomi Galili; Susan T Mayne; Sa A Wang; Herbert Yu; Azra Raza
Journal:  Cancer Causes Control       Date:  2011-02-02       Impact factor: 2.506

4.  Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis.

Authors:  Vijay G Sankaran; Stuart H Orkin; Carl R Walkley
Journal:  Genes Dev       Date:  2008-02-07       Impact factor: 11.361

5.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

6.  MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway.

Authors:  Chutima Kumkhaek; Wulin Aerbajinai; Wenli Liu; Jianqiong Zhu; Naoya Uchida; Roger Kurlander; Matthew M Hsieh; John F Tisdale; Griffin P Rodgers
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

Review 7.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

Review 8.  Formins in development: orchestrating body plan origami.

Authors:  Raymond Liu; Elena V Linardopoulou; Gregory E Osborn; Susan M Parkhurst
Journal:  Biochim Biophys Acta       Date:  2008-10-14

9.  Ras-proximate-1 GTPase-activating protein and Rac2 may play pivotal roles in the initial development of myelodysplastic syndrome.

Authors:  Xuejun Shao; Meihua Miao; Xiaofei Qi; Zixing Chen
Journal:  Oncol Lett       Date:  2012-05-30       Impact factor: 2.967

10.  Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.

Authors:  Wei Zhang; Zonghong Shao; Rong Fu; Huaquan Wang; Lijuan Li; Hui Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.